About the Foundation
NDI Facts & Statistics
Introduction
Description
Diagnosis & Treatment
History of NDI
Patient/Parent Pages
Overview
Medical Alert Cards
Nutrition Guidelines
Low Sodium Diet Basics
Sodium in Foods (6-9 mo.)
Sodium in Foods (9-12 mo.)
Sodium in Foods (toddlers+)
Label Reading Tips
Family Favorite Recipe Tips
Sodium Content of Selected Foods
Sample Meal Patterns
Low Sodium Cookbooks
General Nutrition Guidelines
Other Low Sodium Info
FAQs
NDI: An Overview
Where can I find support?
Health Care
Medications
Diet and Nutrition
Lithium-induced NDI
Pregnancy and NDI
Growth and Development
Behavioral and Social Concerns
What will happen in the future?
Research
Journal Articles
Publishers
Researchers
Terminology
News & Conferences
Foundation News
Global Conferences
2004 - Phoenix
2002 - Heemskerk
2000 - La Jolla
1999 - Amsterdam
1998 - La Jolla
How Can I Help?
Useful Links
Contact Information
Marie-Francoise Arthus
Title:
PhD
Email:
Phone:
Work (514) 338-2722, Fax (514) 338-2569
Organization:
Hopital du Sacre-Coeur de Montreal
Division:
Centre du Recherches et Service de Nephrologie
Address:
5400 Blvd. Gouin Ouest
Montreal, Quebec H4J 1C5
Canada
27 Articles
27 Articles
Pharmacologic Chaperones as a Potential Treatment for X-linked Nephrogenic Diabetes Insipidus
A Novel Mechanism in Recessive Nephrogenic Diabetes Insipidus: Wild-Type Aquaporin-2 Rescues the Apical Membrane Expression of Intracellularly Retained AQP2-P262L
Functional Rescue of the Constitutively Internalized V2 Vasopressin Receptor Mutant R137H by the Pharmacological Chaperone Action of SR49059
Reversed Polarized Delivery of an Aquaporin-2 Mutant Causes Dominant Nephrogenic Diabetes Insipidus
Vasopressin Increases Urinary Albumin Excretion in Rats and Humans: Involvement of V2 Receptors and the Renin-Angiotensin System
Cell-Biologic and Functional Analyses of Five New Aquaporin-2 Missense Mutations that Cause Recessive Nephrogenic Diabetes Insipidus
Two Novel Aquaporin-2 Mutations Responsible for Congenital Nephrogenic Diabetes Insipidus in Chinese Families
Heteroligomerization of an Aquaporin-2 Mutant with Wild-Type Aquaporin-2 and Their Misrouting to Late Endosomes/Lysosomes Explains Dominant Nephrogenic Diabetes Insipidus
Three Families with Autosomal Dominant Nephrogenic Diabetes Insipidus Caused by Aquaporin-2 Mutations in the C-terminus
Association of Calnexin With Wild Type and Mutant AVPR2 that Cause Nephrogenic Diabetes Insipidus
Report of 33 Novel AVPR2 Mutations and Analysis of 117 Families with X-Linked Nephrogenic Diabetes Insipidus
Pharmacological Chaperones Rescue Cell-Surface Expression and Function of Misfolded V2 Vasopressin Receptor Mutants
Functional Studies of Twelve Mutant V
2
Vasopressin Receptors Related to Nephrogenic Diabetes Insipidus: Molecular Basis of a Mild Clinical Phenotype
An Aquaporin-2 Water Channel Mutant Which Causes Autosomal Dominant Nephrogenic Diabetes Insipidus is Retained in the Golgi Complex
Nature and Recurrence of AVPR2 Mutations in X-Linked Nephrogenic Diabetes Insipidus
Mutations in the Vasopressin V2 Receptor Gene in Families with Nephrogenic Diabetes Insipidus and Functional Expression of the Q-2 Mutant
X-Linked Nephrogenic Diabetes Insipidus Mutations in North America and the Hopewell Hypothesis
G
S
-Activating Receptors: Modes of Transmembrane Signalling and Genetic Defects
X-linked Nephrogenic Diabetes Insipidus: from the Ship Hopewell to RFLP Studies
Molecular Identification of the Gene Responsible for Congenital Nephrogenic Diabetes Insipidus
Platelet Vasopressin Receptors in Patients With Congenital Nephrogenic Diabetes Insipidus
Is Testing with dDAVP Useful in Detecting Carriers of the Nephrogenic Diabetes Insipidus Gene?
Rolipram, a Phosphodiesterase Inhibitor, in the Treatment of Two Male Patients with Congenital Nephrogenic Diabetes Insipidus
Epinephrine and dDAVP Administration in Patients with Congenital Nephrogenic Diabetes Insipidus. Evidence for a pre-cyclic AMP V2 Receptor Defective Mechanism
1-Desamino[8-D-arginine]Vasopressin (dDAVP) Decreases Blood Pressure and Increases Pulse Rate in Normal Individuals
Hemodynamic and Coagulation Responses to 1-desamino[8-D-arginine] Vasopressin in Patients with Congenital Nephrogenic Diabetes Insipidus
Human Platelet Fraction Arginine-Vasopressin. Potential Physiological Role
12 Conference Proceedings
12 Conference Proceedings
Diversity of Nephrogenic Diabetes Insipidus Mutations and Importance of Early Recognition and Treatment
Nephrogenic Diabetes Insipidus Mutation Database
Pharmacological chaperones functionally rescue misfolded mutant V2 vasopressin receptors that cause nephrogenic diabetes insipidus
V2 vasopressin receptor mutants responsible for nephrogenic diabetes insipidus associate with the molecular chaperones calnexin and Hsp70
Two new Aquaporin-2 mutations responsible for Congenital Nephrogenic Diabetes Insipidus
Molecular mechanisms underlying dominant Nephrogenic Diabetes Insipidus caused by mutations in the AQP2 gene
Cell biological and functional analysis of five new Aquaporin-2 gene missense mutations in recessive Nephrogenic Diabetes Insipidus
Decrease in urine volume and increase in urine osmolality after SR49059 administration in five adult male patients with X-linked nephrogenic diabetes insipidus
Thirteen Large Deletions/Rearrangements of the AVPR2 Gene Causing X-linked Nephrogenic Diabetes Insipidus
A pharmacological chaperone acting at the V2-vasopressin receptor offers a treatment for Nephrogenic Diabetes Insipidus
Long-range transcriptional regulation of the AVPR2 gene
Clinical and genetic approaches to the diagnosis of congenital polyuro-polydipsic syndromes
27 Articles
27 Articles